Everads Announces Five Abstracts Accepted for Presentation at ARVO 2025, Including First-in-Human Results Using its Novel Suprachoroidal Injector

- Clinical results demonstrate safety, feasibility, and tolerability of the Everads Injector - Additional presentations showcase the broad potential of Everads' platform across gene therapy, small molecules, and suprachoroidal buckling as an innovative approach for the repair of retinal...